Article Details
Retrieved on: 2024-02-23 15:00:04
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight ...
Article found on: www.biopharmadive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here